<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176818">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793572</url>
  </required_header>
  <id_info>
    <org_study_id>2070.00</org_study_id>
    <secondary_id>NCI-2009-01473</secondary_id>
    <secondary_id>MPI X05251</secondary_id>
    <secondary_id>2070.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00793572</nct_id>
  </id_info>
  <brief_title>Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma</brief_title>
  <official_title>Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side-effects and anti-cancer effects of giving an autologous
      or syngeneic stem cell transplant followed by an allogeneic donor stem cell transplant and
      bortezomib. Patients treated on this trial have newly diagnosed high-risk, relapsed, or
      refractory multiple myeloma (MM). Giving chemotherapy before an autologous stem cell
      transplant slows or stops the growth of cancer cells by preventing them from dividing or
      killing them. Stem cells that were harvested earlier from the patient's blood and frozen are
      then returned to the patient to replace the blood-forming cells that were destroyed by
      chemotherapy. Giving chemotherapy and total-body irradiation before an allogeneic donor stem
      cell transplant also prevents the patient's immune system from rejecting the donor's stem
      cells. Undergoing an autologous or syngeneic stem cell transplantation followed by an
      allogeneic donor stem cell transplant and bortezomib may be overall more effective in
      killing cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Progression-free survival (PFS) at 2 years after the autograft (=&lt; 50% in historic
      controls).

      SECONDARY OBJECTIVES:

      I. Overall survival (OS) at 2 years after the autograft.

      II. Non-relapse mortality (NRM) at 200 days and 1 year after allograft.

      III. Incidence of grades II-IV acute graft-versus-host-disease (GVHD) and chronic extensive
      GVHD.

      IV. Safety of bortezomib maintenance therapy after stem cell transplantation.

      OUTLINE:

      PERIPHERAL BLOOD STEM CELL (PBSC) MOBILIZATION: Patients undergo PBSC mobilization and
      collection using the preferred regimens at the participating institution.

      CONDITIONING CHEMOTHERAPY AND AUTOLOGOUS OR SYNGENEIC HEMATOPOIETIC STEM CELL
      TRANSPLANTATION (HSCT): Patients receive high-dose melphalan intravenously (IV) on day -2
      followed by an autologous or syngeneic HSCT on day 0.

      NON-MYELOABLATIVE ALLOGENEIC HSCT: Beginning 40-180 days after autologous HSCT, patients
      receive 1 of the following regimens:

        1. HLA-IDENTICAL RELATED DONOR: Patients receive cyclosporine IV or orally (PO) twice
           daily (BID) starting on days -3 to 56, and taper until day 180. Patients then undergo
           total-body irradiation (TBI) and non-myeloablative allogeneic HSCT on day 0. Four to
           six hours after completion of allogeneic HSCT, patients receive mycophenolate mofetil
           (MMF) PO BID on days 0-27.

        2. HLA-UNRELATED DONOR: Patients receive fludarabine phosphate IV on days -4 to -2.
           Patients also receive cyclosporine IV or PO BID starting on days -3 to 100 and taper
           until day 180. Patients then undergo TBI and non-myeloablative allogeneic HSCT on day
           0. Four to six hours after completion of allogeneic HSCT, patients receive MMF PO
           thrice daily (TID) on days 0-27 and then BID on days 27-40 with taper of MMF on days
           40-96.

      MAINTENANCE THERAPY: Beginning 60-120 days after allogeneic HSCT, patients receive
      bortezomib subcutaneously (SC) on days 1 and 4 of 14-day cycles for 9 months or for up to 18
      cycles in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year and
      then annually for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>At 2 years after the autograft</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades II-IV acute GVHD</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grades II-IV chronic GVHD</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities related to bortezomib maintenance therapy after the stem cell transplantation</measure>
    <time_frame>Up to 100 days after the autograft or allograft</time_frame>
    <description>Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRM</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Confidence intervals will be estimated. Assessed at 200 days and 1 year after allograft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>At 2 years after the autograft</time_frame>
    <description>Estimated by the method of Kaplan and Meier. Confidence intervals will be estimated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>Oforta</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplantation</other_name>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Syngeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed patients must have received induction therapy (e.g., vincristine,
             doxorubicin, dexamethasone [VAD], thalidomide/dexamethasone) for a minimum of 4
             cycles

          -  Must have the capacity to give informed consent

          -  Must have an human leukocyte antigen (HLA) genotypically identical sibling or a
             phenotypically matched relative or, at a minimum, a high likelihood of identifying an
             HLA-matched unrelated donor; the determination of availability of a suitable
             unrelated donor may be based on a World-Book search

          -  In addition, patients must meet at least one of the criteria A-I (A-G at time of
             diagnosis or pre-autograft):

               -  A) Any abnormal karyotype by metaphase analysis except for isolated t(11,14) and
                  constitutional cytogenetic abnormality

               -  B) Fluorescence in situ hybridization (FISH) translocation 4;14

               -  C) FISH translocation 14;16

               -  D) FISH deletion 17p

               -  E) Beta2-microglobulin &gt; 5.5 mg/L

               -  F) Cytogenetic hypodiploidy

               -  G) Plasmablastic morphology (&gt;= 2%)

          -  DONOR: HLA genotypically identical sibling or phenotypically matched relative OR

          -  DONOR: HLA phenotypically matched unrelated donor (according to Standard Practice HLA
             matching criteria, Grade #2.1)

               -  Matched HLA-A, B, C, DRB1, and DQB1 alleles by high resolution typing.

               -  Only a single allele disparity will be allowed for HLA-A, B, or C as defined by
                  high resolution typing

        Exclusion Criteria:

          -  Recurrent or non-responsive (less than partial response [PR]) MM after at least two
             different lines of conventional chemotherapy

          -  Progressive MM after a previous autograft

          -  Life expectancy severely limited by disease other than malignancy

          -  Seropositive for the human immunodeficiency virus (HIV)

          -  Females who are pregnant or breastfeeding

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment

          -  Patients with active non-hematological malignancies (except non-melanoma skin
             cancers) or those with non-hematological malignancies (except non-melanoma skin
             cancers) who have been rendered with no evidence of disease, but have a greater than
             20% chance of having disease recurrence within 5 years; this exclusion does not apply
             to patients with non-hematologic malignancies that do not require therapy

          -  Patients with fungal infection and radiological progression after receipt of
             amphotericin B or active triazole for greater than 1 month

          -  Patients with the following organ dysfunction:

               -  Symptomatic coronary artery disease or ejection fraction &lt; 40% or other cardiac
                  failure requiring therapy; myocardial infarction within 6 months prior to
                  enrollment or has New York Heart Association (NYHA) class III or IV heart
                  failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
                  electrocardiographic evidence of acute ischemia or active conduction system
                  abnormalities

               -  Ejection fraction is required if the patient has a history of anthracyclines or
                  history of cardiac disease

               -  Diffusing lung capacity for carbon monoxide (DLCO) &lt; 50%, forced expiratory
                  volume in 1 second (FEV) &lt; 50% and/or receiving supplementary continuous oxygen;
                  the Fred Hutchinson Cancer Research Center (FHCRC) principle investigator (PI)
                  of the study must approve of enrollment of all patients with pulmonary nodules

               -  Liver function abnormalities: Patient with clinical or laboratory evidence of
                  liver disease will be evaluated for the cause of liver disease, its clinical
                  severity in terms of liver function, bridging fibrosis, and the degree of portal
                  hypertension; the patient will be excluded if he/she is found to have fulminant
                  liver failure; cirrhosis of the liver with evidence of portal hypertension;
                  alcoholic hepatitis; esophageal varices; a history of bleeding esophageal
                  varices; hepatic encephalopathy; uncorrectable hepatic synthetic dysfunction
                  evinced by prolongation of the prothrombin time ascites related to portal
                  hypertension; bacterial or fungal liver abscess; biliary obstruction; chronic
                  viral hepatitis with total serum bilirubin &gt; 3 mg/dL; and symptomatic biliary
                  disease;

               -  Karnofsky score &lt; 70% for adult patients

          -  Patient with poorly controlled hypertension and on multiple antihypertensives

          -  Patients with current &gt;= grade 2 peripheral neuropathy

          -  Patient has an active bacterial or fungal infection unresponsive to medical therapy

          -  DONOR: Identical twin

          -  DONOR: Donors unwilling to donate PBSC

          -  DONOR: Pregnancy

          -  DONOR: Infection with HIV

          -  DONOR: Inability to achieve adequate venous access

          -  DONOR: Known allergy to G-CSF

          -  DONOR: Current serious systemic illness

          -  DONOR: Failure to meet FHCRC criteria for stem cell donation

          -  DONOR: Age &lt; 12 years

          -  DONOR: A positive anti-donor cytotoxic crossmatch

          -  DONOR: Patient and donor pairs must not be homozygous at mismatched allele
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Mielcarek</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>November 18, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
